Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Neuro-Oncology|February 24, 2024
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant gliomaYazmin Odia, Carl Koschmann, Nicholas A Vitanza, et al.
Neuro-Oncology|April 19, 2020
Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trialGirish Dhall, Sharon H O'Neil, Lingyun Ji, et al.
Molecular Cancer Research : MCR|October 23, 2023
Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain TumorsKristyn Galbraith, Jonathan Serrano, Guomiao Shen, et al.
Neuro-Oncology|February 9, 2022
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline gliomaEvan Cantor, Kyle Wierzbicki, Rohinton S Tarapore, et al.
Nature Communications|July 22, 2018
Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastomaMatija Snuderl, Kasthuri Kannan, Elke Pfaff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.
The Lancet. Oncology|October 22, 2013
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
Neuro-Oncology Advances|July 21, 2023
Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testingKristyn Galbraith, Varshini Vasudevaraja, Jonathan Serrano, et al.
Cancer Discovery|August 16, 2023
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Pageof 4